It would be important, in future studies, to analyze the cKIT signaling and metabolism also in erythroid cells expanded from primary myelofibrosis and essential thrombocytopenia in order to evaluate whether these drugs may be effective also in additional myeloproliferative neoplasms. This evidence concerns the gene KIT and myeloproliferative disorder.